Shares of Sensei Biotherapeutics, Inc. (NASDAQ:SNSE – Get Free Report) fell 1.3% during mid-day trading on Wednesday . The stock traded as low as $0.44 and last traded at $0.46. 37,044 shares were traded during mid-day trading, a decline of 68% from the average session volume of 114,842 shares. The stock had previously closed at $0.47.
Analyst Ratings Changes
Separately, HC Wainwright restated a “buy” rating and issued a $4.00 price objective on shares of Sensei Biotherapeutics in a research report on Wednesday, August 7th.
Check Out Our Latest Stock Report on SNSE
Sensei Biotherapeutics Price Performance
Sensei Biotherapeutics (NASDAQ:SNSE – Get Free Report) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.01. Equities analysts anticipate that Sensei Biotherapeutics, Inc. will post -1.11 earnings per share for the current year.
Sensei Biotherapeutics Company Profile
Sensei Biotherapeutics, Inc, an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment.
Featured Articles
- Five stocks we like better than Sensei Biotherapeutics
- What is Put Option Volume?
- Taiwan Semiconductor Stock: Buy Now or Wait for Earnings?
- What is a Special Dividend?
- Abbott’s Growth and Dividends Make It a Smart Portfolio Pick
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Citigroup Faces Growing Troubles: Could the Industry Be at Risk?
Receive News & Ratings for Sensei Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensei Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.